Inhibitory Effect of Amentoflavone on the Virulence of MRSA by Targeting ClpP

Area of Science:

• Microbiology
• Pharmacology
• Computational Biology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) presents a significant global health threat due to its increasing virulence and resistance to antibiotics.
• Targeting bacterial virulence factors, rather than essential survival mechanisms, offers a promising antivirulence strategy to combat resistant pathogens.
• The ClpP protease is a critical regulator of virulence in many bacteria, including MRSA, making it an attractive therapeutic target.

Purpose of the Study:

• To investigate the mechanism of action of a novel compound, AMF, as an inhibitor of MRSA virulence by targeting the ClpP protease.
• To evaluate the efficacy of AMF in reducing MRSA virulence factors, including haemolytic activity and biofilm formation, both in vitro and in vivo.
• To assess the therapeutic potential of AMF in a murine model of MRSA pneumonia.

Main Methods:

• Molecular dynamics simulations, Förster Resonance Energy Transfer (FRET), and Thermal Shift Assay (TSA) were employed to study AMF-ClpP interactions.
• Phenotypic assays were conducted to measure MRSA haemolytic activity, biofilm formation, and bacterial growth.
• In vivo studies included a murine pneumonia model to assess survival rates, cytokine levels, and lung tissue damage.

Main Results:

• AMF significantly inhibited MRSA haemolytic activity (72%) and biofilm formation (58%) without affecting bacterial growth.
• Molecular docking and CETSA identified key interaction sites between AMF and ClpP (ARG-171, ASP-170, ASP-172).
• AMF treatment in mice improved survival rates from 20% to 75% and reduced pro-inflammatory cytokines, mitigating lung damage.

Conclusions:

• AMF is a potent ClpP inhibitor that effectively attenuates MRSA virulence through dual mechanisms: suppression of toxin production and biofilm formation.
• AMF demonstrates significant therapeutic potential as an antivirulence agent against MRSA infections, offering a promising alternative to conventional antibiotics.
• Targeting ClpP represents a viable antivirulence strategy for combating challenging bacterial pathogens like MRSA, preserving the host microbiome.